Completed PHASE3 INTERVENTIONAL 2-arm NCT00235248

Aortic Arch Related Cerebral Hazard Trial (ARCH) (ARCH)

Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Brain Infarction Embolism Transient Ischemic Attack

Interventions Clopidogrel-aspirin Warfarin

Updated 5 times since 2017 Last updated: Jul 6, 2012 Started: Feb 28, 2002 Primary completion: Dec 31, 2010 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Brain Infarction and Embolism and is currently completed. Assistance Publique - Hôpitaux de Paris leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris
Bristol-Myers Squibb
National Health and Medical Research Council, Australia
Sanofi

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heidelberg Heights, Australia
• Paris, France